AKTS
Aktis Oncology, Inc. Common stock
NASDAQ: AKTS · HEALTHCARE · BIOTECHNOLOGY
$16.82
+2.25% today
Updated 2026-10-28
Market cap
$837.63M
P/E ratio
—
P/S ratio
83.26x
EPS (TTM)
$-1.70
Dividend yield
—
52W range
$15 – $34
Volume
0.4M
WallStSmart proprietary scores
35
out of 100
Grade: D
Sell
Investment rating
6.3
Growth
B6.5
Quality
B2.5
Profitability
F5.0
Valuation
C+2/9
Piotroski F-Score
Weak
-0.7
Altman Z-Score
Distress
—
Industry rank
—
View all highly rated stocks (75+) →270 stocks currently score above 75
Price targets
Analyst target
$35.39
+110.40%
12-Month target
—
—
Intrinsic (DCF)
—
Margin of safety
—
1 Strong Buy9 Buy0 Hold0 Sell0 Strong Sell
Price chart
Stock snapshot
Strengths
+ Revenue growth 111.40% QoQ
+ Debt/equity 0.02x — low leverage
Risks
- Piotroski 2/9 — weak financial health
- Altman Z -0.70 — distress zone
- Thin margins at 0.00%
- Negative free cash flow $-21.85M
Key financials
Revenue Net Income Free Cash Flow
| Metric | 2022 | 2023 | 2024 | 2025 | TTM |
|---|---|---|---|---|---|
| Revenue | $0.00 | $27.12M | $1.49M | $6.50M | $10.06M |
| Net income | $-17.93M | $-28.64M | $-43.98M | $-63.73M | $-24.14M |
| EPS | — | — | — | — | $-1.70 |
| Free cash flow | $-20.43M | $-33.77M | $11.90M | $-73.71M | $-21.85M |
| Profit margin | — | -105.60% | -2,957.63% | -980.93% | — |
Recent insider activity
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| 2024-01-29 | SHEALY, JEFFREY B. | Buy | 1,310,000 | $0.50 |
| 2024-01-29 | GEISS, ARTHUR | Buy | 50,000 | $0.50 |
| 2024-01-29 | BOLLER, KENNETH | Buy | 60,000 | $0.50 |
Peer comparison
Smart narrative
Aktis Oncology, Inc. Common stock trades at $16.82. Our Smart Value Score of 35/100 indicates the stock is weak. The company scores 2/9 on the Piotroski F-Score. With an Altman Z-Score of -0.70, it sits in the distress. TTM revenue stands at $10.06M.
Frequently asked questions
What is Aktis Oncology, Inc. Common stock's stock price?
Aktis Oncology, Inc. Common stock (AKTS) trades at $16.82, on a P/S of 83.3x. Those multiples show what the market is paying for each dollar of earnings and sales, which is the real starting point for judging whether the price is reasonable.
Is Aktis Oncology, Inc. Common stock overvalued?
Aktis Oncology, Inc. Common stock carries a Smart Value Score of 35/100 (Grade D), which we rate Sell. That score blends growth, quality, and valuation into one read.
What is the price target of Aktis Oncology, Inc. Common stock (AKTS)?
The 12-month analyst consensus target is $35.39, about 110.4% above the current $16.82. A consensus target is the average of Wall Street's 12-month forecasts, so it works as a sentiment gauge rather than a guarantee, and it resets with every earnings cycle.
What is Aktis Oncology, Inc. Common stock's revenue?
Aktis Oncology, Inc. Common stock's trailing twelve-month revenue is $10.06M. Revenue scale anchors the valuation multiples and shows whether growth is reaching the top line, so it is best read alongside margin and growth trends to see if that revenue is getting more profitable over time.
Altman Z-Score?
Aktis Oncology, Inc. Common stock's Altman Z-Score is -0.70, which places it in the distress. The Altman Z-Score gauges bankruptcy risk from profitability, leverage, and asset efficiency, and a higher reading points to lower financial distress risk.
Company info
SectorHEALTHCARE
IndustryBIOTECHNOLOGY
CountryUSA
ExchangeNASDAQ
CurrencyUSD
Quick metrics
P/S ratio83.26x
ROE-15.09%
Beta—
50D MA$22.22
200D MA$21.28
Shares out0.05B
Float0.03B
Short ratio—
Avg volume0.4M
Performance
1 week+0.18%
1 month-14.99%
3 months-26.53%
YTD—
1 year—
3 years—
5 years—